Clinical efficacy of the first two doses of anti‐SARS‐CoV‐2 mRNA vaccines in solid cancer patients

INTRODUCTION: Cancer patients are frail individuals, thus the prevention of SARS‐CoV‐2 infection is essential. To date, vaccination is the most effective tool to prevent COVID‐19. In a previous study, we evaluated the immunogenicity of two doses of mRNA‐based vaccines (BNT162b2 or mRNA‐1273) in soli...

Descripción completa

Detalles Bibliográficos
Autores principales: Cona, Maria Silvia, Riva, Agostino, Dalu, Davide, Gabrieli, Arianna, Fasola, Cinzia, Lipari, Giuseppe, Pozza, Giacomo, Rulli, Eliana, Galli, Francesca, Ruggieri, Lorenzo, Masedu, Elsa, Parma, Gaia, Chizzoniti, Davide, Gambaro, Anna, Ferrario, Sabrina, Antista, Maria, De Monte, Matteo, Tarkowski, Maciej S., La Verde, Nicla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315797/
https://www.ncbi.nlm.nih.gov/pubmed/37114577
http://dx.doi.org/10.1002/cam4.5968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315797/
https://www.ncbi.nlm.nih.gov/pubmed/37114577
http://dx.doi.org/10.1002/cam4.5968

Ejemplares similares